Lei Jianping on May 14
InnoCare Pharma Co., Ltd. (stock code: 688428, stock abbreviation: InnoCare) recently released its financial report. According to the financial report, InnoCare's revenue in the first quarter of 2024 was 166 million yuan, a year-on-year decrease of 12.44%.
InnoCare's core product orelabrutinib (Innochem ®) continued to grow in sales revenue, with a total sales revenue of RMB164 million from January to March 2024, a year-on-year increase of 9%.
In 2024, with the implementation of the new National Medical Insurance Catalog, orelabrutinib will be indicated for three indications: adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior treatment (r/rCLL/SLL), adult mantle cell lymphoma (MCL) patients who have received at least one prior treatment (r/rMCL), and adult patients with marginal zone lymphoma (MZL) who have received at least one prior therapy (r/ rMZL) are covered by health insurance.
Among them, orelabrutinib is the first and only BTK inhibitor approved for the indication of MZL in China, and has been listed as a Class I recommended regimen for the second-line treatment of marginal zone lymphoma (MZL) by the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Lymphoma 2024.
InnoCare's gross profit margin from January to March 2024 was 85.4%, an increase of 8.1 percentage points from 77.3% in the same period last year. As of March 31, 2024, the company held monetary funds of approximately 8.2 billion yuan.
InnoCare's R&D investment in the first quarter of 2024 was RMB178 million, a year-on-year increase of 26.09%, accounting for 107.18% of revenue.
InnoCare's net loss for the first quarter of 2024 was RMB142 million, and the net loss after deducting non-profits was RMB134 million.
Hillhouse is the majority shareholder
截至2024年3月31日，高瓴旗下HHLR及其一致行动人持股为11.8389%，King Bridge Investments Limited 及其一致行动人持股9.0202%，Sunny ViewHoldings Limited与 Renbin Zhao（赵仁滨、施一公）家族持股为8.2049%，Vivo Capital Fund VIII,L.P.及其一致行动人持股为7.3265%；
As of March 31, 2024, InnoCare's shareholding structure
Sunland BioMed Ltd and Jisong Cui (Cui Jisong) family hold 7.1413% of the shares, Bank of Communications Co., Ltd. - Wanjia Industry Preferred Hybrid Securities Investment Fund (LOF) holds 1.1347%, Agricultural Bank of China Co., Ltd. - Penghua Pharmaceutical Technology Equity Securities Investment Fund holds 1.0865%, and Guangzhou High-tech Zone Technology Holding Group Co., Ltd. holds 0.5092%. Bohai Bank Co., Ltd.-China Securities Construction Investment Medical Reform Flexible Allocation Hybrid Securities Investment Fund holds 0.5049% of the shares.
截至2023年12月31日,高瓴旗下HHLR及其一致行动人持股为11.83%,King Bridge Investments Limited 及其一致行动人持股9.009%,Sunny ViewHoldings Limited与 Renbin Zhao(赵仁滨、施一公)家族持股为8.2023%,Sunland BioMedLtd 与 Jisong Cui(崔霁松)家族持股7.1391%;
As of December 31, 2023, InnoCare's shareholding structure
Vivo Capital Fund VIII, L.P. and its concert parties hold 7.3243% of the shares, Bank of Communications Co., Ltd. - Wanjia Industry Preferred Hybrid Securities Investment Fund (LOF) holds 1.1343% of the shares, Agricultural Bank of China Co., Ltd. - Penghua Pharmaceutical Technology Equity Securities Investment Fund holds 1.0862% of the shares, and Guangzhou High-tech Zone Technology Holding Group Co., Ltd. holds 0.5091% of the shares. Bohai Bank Co., Ltd.-China Securities Construction Investment Investment Medical Reform Flexible Allocation Hybrid Securities Investment Fund holds 0.5048% of the shares.
In contrast, InnoCare's equity in the first quarter of 2024 has not changed much.
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.